Interneuron"Interneuron Pharmaceuticals (IPIC, OTC, around...

STOCK WATCH

November 06, 1991|By Opinions on stocks offered by investment experts. Compiled by Steve Halpern for Knight-Ridder.

Interneuron

"Interneuron Pharmaceuticals (IPIC, OTC, around $9) is a promising young company, which began operations in 1990," says R.H.M. Survey of Warrants and Options, Glen Cove, N.Y.

"Wall Street is only beginning to become aware of the firm's new products. . .

"And we expect many exciting things over the next year or so.

"We believe that the true merits of the company's products will soon become even more evident and recommend purchase at current levels."

Isis

Isis Pharmaceuticals (ISIP, OTC, around $21) is one of the more exciting start-up companies to emerge," says Teena Lerner of Shearson Lehman Brothers.

"The firm has a leadership position in a new and broadly applicable technology known as anti-sense chemistry. Over the next two to three years, if Isis can take several new molecules into clinical trials and generate positive data (which is our expectation), the upside potential in the stock could be as high as $35 a share. The stock is a speculative buy."

St. Jude Medical

"St. Jude (STJM, OTC, around $47) is the world's largest maker of mechanical heart valves, accounting for over half of all valves implanted to date," says the Marketarian Letter of Grand Island, Neb.

"The company has a magnificent track record for growth and an excellent history of stock splits. The introduction of new opportunities in Europe, a new centrifugal blood-pump system, and the establishment of a new independent sales force should boost earnings. The stock is an excellent addition to most portfolios."

Cordis Corp.

"The driving force behind sales growth of Cordis (CORD, OTC, around $38) is its move into the angioplasty market; angioplasty involves opening clogged arteries without major surgery," says BI Research of Redding. Conn.

"The angioplasty market is twice the size of the diagnosis market, the area in which Cordis was previously active. Profit margins in this new field also are higher. Success in this field could stimulate the company's bottom line. We continue to recommend purchase of these shares."

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.